Leading Non-Profits Forge Agreement for Gene Therapy Access to Combat Ultra-Rare Diseases Orphan Therapeutics Accelerator and Fondazione Telethon unite to enhance patient access to innovative gene therapies for ultra-rare diseases, revolutionizing treatment models in the U.S.

Leading Non-Profits Forge Agreement for Gene Therapy Access to Combat Ultra-Rare Diseases #United_States #Cambridge #Fondazione_Telethon #Wiskott-Aldrich_Syndrome #Orphan_Therapeutics

Fondazione Telethon Celebrates FDA Approval of Waskyra™ Gene Therapy for WAS Treatment Fondazione Telethon has announced that the FDA approved Waskyra™, a groundbreaking gene therapy for Wiskott-Aldrich Syndrome (WAS), providing hope for patients.

Fondazione Telethon Celebrates FDA Approval of Waskyra™ Gene Therapy for WAS Treatment #USA #Rome #Fondazione_Telethon #Wiskott-Aldrich #Waskyra

FDA Approval of Waskyra™ Marks a Milestone in Wiskott-Aldrich Syndrome Treatment Fondazione Telethon proudly announces FDA approval for Waskyra™, a groundbreaking gene therapy for Wiskott-Aldrich Syndrome, offering new hope for patients.

FDA Approval of Waskyra™ Marks a Milestone in Wiskott-Aldrich Syndrome Treatment #Italy #Milan #Fondazione_Telethon #Wiskott-Aldrich #Waskyra

Fondazione Telethon Paves Way for Waskyra™ Gene Therapy Against Wiskott-Aldrich Syndrome Fondazione Telethon announces CHMP's positive opinion on Waskyra™, a gene therapy for Wiskott-Aldrich syndrome, advancing treatment options for patients.

Fondazione Telethon Paves Way for Waskyra™ Gene Therapy Against Wiskott-Aldrich Syndrome #Italy #Rome #Fondazione_Telethon #Wiskott-Aldrich #Waskyra